Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Illinois: - Rush - Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Memorial Hospital of Carbondale — Carbondale, Illinois
- SIH Cancer Institute — Carterville, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Illinois: - Centralia Oncology Clinic — Centralia, Illinois
- Northwestern University — Chicago, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Carle at The Riverfront — Danville, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Illinois: - Rush-Copley Medical Center — Aurora, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Carle at The Riverfront — Danville, Illinois
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Saint Jude Midwest Affiliate — Peoria, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Illinois: - University of Illinois — Chicago, Illinois
- Saint Jude Midwest Affiliate — Peoria, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Saint Jude Midwest Affiliate — Peoria, Illinois
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Illinois: - University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Saint Jude Midwest Affiliate — Peoria, Illinois
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Phase 2 Recruiting NIH
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Illinois: - Memorial Hospital East — Shiloh, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Illinois: - Robert H. Lurie Comprehensive Cancer Center Northwestern University — Chicago, Illinois
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Illinois: - Lurie Children's Hospital of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Illinois: - Research Site — Chicago, Illinois
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…
Sponsor: Debiopharm International SA
NCT ID: NCT05765812
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois
Phase 2 Recruiting Academic/Other
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose ch…
Sponsor: Medical University of Vienna
NCT ID: NCT01356290
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are contro…
Sponsor: Northwestern University
NCT ID: NCT05879250
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Northwestern Medicine: Warrenville — Warrenville, Illinois
Phase 2 Recruiting Academic/Other
This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.
Sponsor: University of Chicago
NCT ID: NCT02747303
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1 Recruiting Network
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…
Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
EARLY Phase 1 Recruiting Academic/Other
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with che…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06333899
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
Phase 1 Recruiting Industry
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Sponsor: Boston Scientific Corporation
NCT ID: NCT05303467
Sites in Illinois: - Northwestern Univerity — Chicago, Illinois
Phase 1 Recruiting Industry
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and p…
Sponsor: Tetragon Biosciences Ltd
NCT ID: NCT07464925
Sites in Illinois: - Northwestern Medicine — Chicago, Illinois
Phase 1 Recruiting Academic/Other
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containin…
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
NCT ID: NCT04943848
Sites in Illinois: - Ann and Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois